Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
Biochem/physiol Actions CuATSP is a CuATSM analog with >:10-fold enhanced ferropotosis inhibitory potency (CuATSP/CuATSM IC50 against 150 nM RSL3-induced ferroptosis = 8.5/160 nM using Pfa1 mouse embryonic fibroblasts,16/170 nM using HT-22 mouse
Biochem/physiol Actions CuATSP is a CuATSM analog with >:10-fold enhanced ferropotosis inhibitory potency (CuATSP/CuATSM IC50 against 150 nM RSL3-induced ferroptosis = 8.5/160 nM using Pfa1 mouse embryonic fibroblasts,16/170 nM using HT-22 mouse
Biochem/physiol Actions CuATSP is a CuATSM analog with >:10-fold enhanced ferropotosis inhibitory potency (CuATSP/CuATSM IC50 against 150 nM RSL3-induced ferroptosis = 8.5/160 nM using Pfa1 mouse embryonic fibroblasts,16/170 nM using HT-22 mouse
Biochem/physiol Actions CuATSP is a CuATSM analog with >:10-fold enhanced ferropotosis inhibitory potency (CuATSP/CuATSM IC50 against 150 nM RSL3-induced ferroptosis = 8.5/160 nM using Pfa1 mouse embryonic fibroblasts,16/170 nM using HT-22 mouse